17/10/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 2.8 million subscribed by a limited number of investors Download PDF Category: 2025By Alexis BERNARD17 October 2025 Partager cet article Share on LinkedInShare on LinkedIn Share on XShare on X Share on FacebookShare on Facebook Share on WhatsAppShare on WhatsApp Pin itShare on Pinterest Author: Alexis BERNARD Post navigationPreviousPrevious post:Summary of the virtual conference held on October 16, 2025NextNext post:AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of functionRelated PostsAB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 204022 December 2025AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share18 December 2025AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers15 December 2025AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function11 December 2025Summary of the virtual conference held on October 16, 202516 October 2025AB Science webcast of October 16, 202516 October 2025
AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 204022 December 2025
AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share18 December 2025
AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers15 December 2025
AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function11 December 2025
